Can a drug stop the agony of mouth sores during cancer therapy?

NCT ID NCT03387774

Completed Symptom relief Sponsor: Sun Yat-sen University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 3 trial tested whether ulinastatin, a drug that blocks certain enzymes, can reduce severe mouth sores caused by chemoradiotherapy in 179 patients with advanced nasopharyngeal cancer. Patients received either standard care or ulinastatin alongside their cancer treatment. The goal was to see if fewer patients developed painful, severe oral mucositis.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ulinastatin
What this could lead to: If it works, this could provide a new way to reduce painful mouth sores during cancer treatment, improving patients' quality of life.
What could go wrong: This is a completed phase 3 trial, but results are not yet widely confirmed. The drug may not significantly reduce severe mucositis compared to standard care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NASOPHARYNGEAL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

nasopharyngeal carcinoma stomatitis ulcer disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ORAL MUCOSITIS (ULCERATIVE) DUE TO RADIATION

Contacts and locations

Locations

Cancer Center, Sun Yat-sen University

Guangzhou, Guangdong, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.